nodes	percent_of_prediction	percent_of_DWPC	metapath
Fingolimod—CYP2D6—Hydroxyurea—psoriasis	0.0603	0.149	CbGbCtD
Fingolimod—CYP3A4—Calcitriol—psoriasis	0.0451	0.111	CbGbCtD
Fingolimod—CYP2D6—Cholecalciferol—psoriasis	0.0365	0.0901	CbGbCtD
Fingolimod—CYP3A4—Methoxsalen—psoriasis	0.0351	0.0865	CbGbCtD
Fingolimod—CYP2E1—Dexamethasone—psoriasis	0.0332	0.0818	CbGbCtD
Fingolimod—CYP2D6—Cyclosporine—psoriasis	0.024	0.0592	CbGbCtD
Fingolimod—CYP3A4—Cholecalciferol—psoriasis	0.0232	0.0573	CbGbCtD
Fingolimod—CYP3A4—Triamcinolone—psoriasis	0.0201	0.0497	CbGbCtD
Fingolimod—CYP3A4—Mycophenolate mofetil—psoriasis	0.0201	0.0497	CbGbCtD
Fingolimod—CYP3A4—Betamethasone—psoriasis	0.0173	0.0426	CbGbCtD
Fingolimod—CYP3A4—Prednisolone—psoriasis	0.017	0.0421	CbGbCtD
Fingolimod—CYP3A4—Hydrocortisone—psoriasis	0.0162	0.0399	CbGbCtD
Fingolimod—CYP3A4—Prednisone—psoriasis	0.0161	0.0397	CbGbCtD
Fingolimod—CYP2D6—Dexamethasone—psoriasis	0.0158	0.039	CbGbCtD
Fingolimod—CYP3A4—Cyclosporine—psoriasis	0.0153	0.0376	CbGbCtD
Fingolimod—S1PR1—endothelium—psoriasis	0.0101	0.364	CbGeAlD
Fingolimod—CYP3A4—Dexamethasone—psoriasis	0.0101	0.0248	CbGbCtD
Fingolimod—CYP4F12—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00938	0.0395	CbGpPWpGaD
Fingolimod—CYP4F2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.0082	0.0345	CbGpPWpGaD
Fingolimod—CYP4F2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00809	0.0341	CbGpPWpGaD
Fingolimod—CYP4F12—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0077	0.0324	CbGpPWpGaD
Fingolimod—CYP4F2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00665	0.028	CbGpPWpGaD
Fingolimod—S1PR5—skin of body—psoriasis	0.00587	0.212	CbGeAlD
Fingolimod—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00449	0.0189	CbGpPWpGaD
Fingolimod—SPHK1—skin of body—psoriasis	0.00426	0.154	CbGeAlD
Fingolimod—CYP4F12—Biological oxidations—CYP2S1—psoriasis	0.00409	0.0172	CbGpPWpGaD
Fingolimod—CYP4F12—Metapathway biotransformation—CYP2S1—psoriasis	0.00404	0.017	CbGpPWpGaD
Fingolimod—S1PR3—tendon—psoriasis	0.00371	0.134	CbGeAlD
Fingolimod—CYP4F2—Biological oxidations—CYP2S1—psoriasis	0.00353	0.0149	CbGpPWpGaD
Fingolimod—CYP4F12—Tryptophan metabolism—CAT—psoriasis	0.00353	0.0149	CbGpPWpGaD
Fingolimod—CYP4F2—Metapathway biotransformation—CYP2S1—psoriasis	0.00348	0.0147	CbGpPWpGaD
Fingolimod—S1PR4—G alpha (i) signalling events—HCAR2—psoriasis	0.00338	0.0142	CbGpPWpGaD
Fingolimod—S1PR5—G alpha (i) signalling events—HCAR2—psoriasis	0.00325	0.0137	CbGpPWpGaD
Fingolimod—S1PR3—G alpha (i) signalling events—HCAR2—psoriasis	0.00325	0.0137	CbGpPWpGaD
Fingolimod—SPHK1—tendon—psoriasis	0.00324	0.117	CbGeAlD
Fingolimod—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00319	0.0134	CbGpPWpGaD
Fingolimod—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00298	0.0125	CbGpPWpGaD
Fingolimod—S1PR1—G alpha (i) signalling events—HCAR2—psoriasis	0.00295	0.0124	CbGpPWpGaD
Fingolimod—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00279	0.0117	CbGpPWpGaD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00269	0.0113	CbGpPWpGaD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00259	0.0109	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00259	0.0109	CbGpPWpGaD
Fingolimod—S1PR1—S1P1 pathway—VEGFA—psoriasis	0.00252	0.0106	CbGpPWpGaD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00235	0.00989	CbGpPWpGaD
Fingolimod—SPHK1—S1P1 pathway—VEGFA—psoriasis	0.00223	0.00938	CbGpPWpGaD
Fingolimod—S1PR3—S1P3 pathway—VEGFA—psoriasis	0.00223	0.00937	CbGpPWpGaD
Fingolimod—S1PR4—GPCR ligand binding—HCAR2—psoriasis	0.00205	0.00861	CbGpPWpGaD
Fingolimod—SPHK1—VEGFR2 mediated cell proliferation—TYK2—psoriasis	0.00198	0.00832	CbGpPWpGaD
Fingolimod—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00198	0.00832	CbGpPWpGaD
Fingolimod—S1PR3—GPCR ligand binding—HCAR2—psoriasis	0.00197	0.00829	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—HCAR2—psoriasis	0.00197	0.00829	CbGpPWpGaD
Fingolimod—S1PR1—GPCR ligand binding—HCAR2—psoriasis	0.00179	0.00753	CbGpPWpGaD
Fingolimod—S1PR4—G alpha (i) signalling events—CCL20—psoriasis	0.00176	0.00739	CbGpPWpGaD
Fingolimod—S1PR3—G alpha (i) signalling events—CCL20—psoriasis	0.00169	0.00711	CbGpPWpGaD
Fingolimod—S1PR5—G alpha (i) signalling events—CCL20—psoriasis	0.00169	0.00711	CbGpPWpGaD
Fingolimod—S1PR1—G alpha (i) signalling events—CCL20—psoriasis	0.00153	0.00646	CbGpPWpGaD
Fingolimod—SPHK1—VEGFR2 mediated cell proliferation—VEGFA—psoriasis	0.0014	0.00589	CbGpPWpGaD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.0014	0.00587	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00134	0.00566	CbGpPWpGaD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00134	0.00566	CbGpPWpGaD
Fingolimod—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00129	0.00544	CbGpPWpGaD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00122	0.00514	CbGpPWpGaD
Fingolimod—SPHK1—Beta3 integrin cell surface interactions—VEGFA—psoriasis	0.00116	0.00488	CbGpPWpGaD
Fingolimod—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00116	0.00487	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—HCAR2—psoriasis	0.00116	0.00487	CbGpPWpGaD
Fingolimod—SPHK1—Betamethasone—Clobetasol propionate—psoriasis	0.00115	0.0968	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Clobetasol propionate—psoriasis	0.00115	0.0968	CbGdCrCtD
Fingolimod—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00114	0.00481	CbGpPWpGaD
Fingolimod—S1PR1—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.00113	0.00477	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—HCAR2—psoriasis	0.00111	0.00469	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—HCAR2—psoriasis	0.00111	0.00469	CbGpPWpGaD
Fingolimod—S1PR1—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.00109	0.00459	CbGpPWpGaD
Fingolimod—S1PR4—GPCR ligand binding—CCL20—psoriasis	0.00106	0.00447	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—HCAR2—psoriasis	0.00105	0.00442	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—CCL20—psoriasis	0.00102	0.00431	CbGpPWpGaD
Fingolimod—S1PR3—GPCR ligand binding—CCL20—psoriasis	0.00102	0.00431	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—HCAR2—psoriasis	0.00101	0.00425	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—HCAR2—psoriasis	0.00101	0.00425	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—HCAR2—psoriasis	0.00101	0.00425	CbGpPWpGaD
Fingolimod—SPHK1—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.001	0.00422	CbGpPWpGaD
Fingolimod—SPHK1—VEGFR2 mediated cell proliferation—IL6—psoriasis	0.000967	0.00407	CbGpPWpGaD
Fingolimod—SPHK1—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000965	0.00406	CbGpPWpGaD
Fingolimod—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000938	0.00395	CbGpPWpGaD
Fingolimod—S1PR1—GPCR ligand binding—CCL20—psoriasis	0.000929	0.00391	CbGpPWpGaD
Fingolimod—SPHK1—Dexamethasone—Beclomethasone—psoriasis	0.000923	0.0775	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Fluocinonide—psoriasis	0.000923	0.0775	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Beclomethasone—psoriasis	0.000923	0.0775	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Fluocinonide—psoriasis	0.000923	0.0775	CbGdCrCtD
Fingolimod—S1PR1—Signaling by GPCR—HCAR2—psoriasis	0.000918	0.00386	CbGpPWpGaD
Fingolimod—SPHK1—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000897	0.0754	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000897	0.0754	CbGdCrCtD
Fingolimod—CYP4F12—Metabolism—NDUFA5—psoriasis	0.000823	0.00346	CbGpPWpGaD
Fingolimod—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000821	0.00346	CbGpPWpGaD
Fingolimod—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00081	0.00341	CbGpPWpGaD
Fingolimod—SPHK1—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	0.00079	0.00333	CbGpPWpGaD
Fingolimod—SPHK1—Signaling by VEGF—TYK2—psoriasis	0.000746	0.00314	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—NDUFA5—psoriasis	0.00071	0.00299	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—CYP2S1—psoriasis	0.0007	0.00295	CbGpPWpGaD
Fingolimod—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000666	0.0028	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000662	0.00279	CbGpPWpGaD
Fingolimod—S1PR1—PDGFR-beta signaling pathway—JUN—psoriasis	0.000638	0.00269	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—HCAR2—psoriasis	0.00062	0.00261	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—NDUFA5—psoriasis	0.00061	0.00257	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—REN—psoriasis	0.000606	0.00255	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—CYP2S1—psoriasis	0.000604	0.00254	CbGpPWpGaD
Fingolimod—S1PR4—GPCR downstream signaling—CCL20—psoriasis	0.000601	0.00253	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—HCAR2—psoriasis	0.000597	0.00251	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—HCAR2—psoriasis	0.000597	0.00251	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—CCL20—psoriasis	0.000578	0.00243	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—CCL20—psoriasis	0.000578	0.00243	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000569	0.0024	CbGpPWpGaD
Fingolimod—SPHK1—PDGFR-beta signaling pathway—JUN—psoriasis	0.000565	0.00238	CbGpPWpGaD
Fingolimod—SPHK1—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	0.000559	0.00235	CbGpPWpGaD
Fingolimod—Eye disorder—Mycophenolic acid—psoriasis	0.000553	0.00174	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Acitretin—psoriasis	0.000552	0.00174	CcSEcCtD
Fingolimod—S1PR1—PDGFR-beta signaling pathway—STAT3—psoriasis	0.000552	0.00232	CbGpPWpGaD
Fingolimod—Fatigue—Acitretin—psoriasis	0.000552	0.00174	CcSEcCtD
Fingolimod—Cardiac arrest—Triamcinolone—psoriasis	0.000551	0.00174	CcSEcCtD
Fingolimod—Leukopenia—Hydroxyurea—psoriasis	0.000551	0.00174	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000551	0.00174	CcSEcCtD
Fingolimod—Cardiac disorder—Mycophenolic acid—psoriasis	0.00055	0.00173	CcSEcCtD
Fingolimod—S1PR4—Signaling by GPCR—CCL20—psoriasis	0.000545	0.0023	CbGpPWpGaD
Fingolimod—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000543	0.00171	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—HCAR2—psoriasis	0.000542	0.00228	CbGpPWpGaD
Fingolimod—Weight decreased—Cyclosporine—psoriasis	0.000542	0.00171	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—TAGAP—psoriasis	0.000538	0.00226	CbGpPWpGaD
Fingolimod—Angiopathy—Mycophenolic acid—psoriasis	0.000537	0.00169	CcSEcCtD
Fingolimod—Pneumonia—Cyclosporine—psoriasis	0.000537	0.00169	CcSEcCtD
Fingolimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000537	0.00226	CbGpPWpGaD
Fingolimod—Mediastinal disorder—Mycophenolic acid—psoriasis	0.000534	0.00168	CcSEcCtD
Fingolimod—Infestation NOS—Cyclosporine—psoriasis	0.000534	0.00168	CcSEcCtD
Fingolimod—Infestation—Cyclosporine—psoriasis	0.000534	0.00168	CcSEcCtD
Fingolimod—Dizziness—Methoxsalen—psoriasis	0.000534	0.00168	CcSEcCtD
Fingolimod—Depression—Cyclosporine—psoriasis	0.000532	0.00168	CcSEcCtD
Fingolimod—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000531	0.00224	CbGpPWpGaD
Fingolimod—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00053	0.00223	CbGpPWpGaD
Fingolimod—Weight decreased—Mycophenolate mofetil—psoriasis	0.000528	0.00166	CcSEcCtD
Fingolimod—SPHK1—Signaling by VEGF—VEGFA—psoriasis	0.000528	0.00222	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CCL20—psoriasis	0.000525	0.00221	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CCL20—psoriasis	0.000525	0.00221	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—CCL20—psoriasis	0.000525	0.00221	CbGpPWpGaD
Fingolimod—CYP2E1—tendon—psoriasis	0.000525	0.019	CbGeAlD
Fingolimod—Pneumonia—Mycophenolate mofetil—psoriasis	0.000524	0.00165	CcSEcCtD
Fingolimod—Alopecia—Mycophenolic acid—psoriasis	0.000523	0.00165	CcSEcCtD
Fingolimod—Infestation NOS—Mycophenolate mofetil—psoriasis	0.000521	0.00164	CcSEcCtD
Fingolimod—Infestation—Mycophenolate mofetil—psoriasis	0.000521	0.00164	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.00052	0.00164	CcSEcCtD
Fingolimod—Depression—Mycophenolate mofetil—psoriasis	0.000519	0.00164	CcSEcCtD
Fingolimod—SPHK1—Metabolism—CYP2S1—psoriasis	0.000519	0.00218	CbGpPWpGaD
Fingolimod—Mental disorder—Mycophenolic acid—psoriasis	0.000519	0.00163	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—TAGAP—psoriasis	0.000518	0.00218	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TAGAP—psoriasis	0.000518	0.00218	CbGpPWpGaD
Fingolimod—Migraine—Dexamethasone—psoriasis	0.000518	0.00163	CcSEcCtD
Fingolimod—Migraine—Betamethasone—psoriasis	0.000518	0.00163	CcSEcCtD
Fingolimod—Asthenia—Calcitriol—psoriasis	0.000516	0.00163	CcSEcCtD
Fingolimod—Pruritus—Calcitriol—psoriasis	0.000509	0.0016	CcSEcCtD
Fingolimod—Headache—Methoxsalen—psoriasis	0.000506	0.00159	CcSEcCtD
Fingolimod—Influenza—Triamcinolone—psoriasis	0.000501	0.00158	CcSEcCtD
Fingolimod—Sinusitis—Cyclosporine—psoriasis	0.000501	0.00158	CcSEcCtD
Fingolimod—Cardiac arrest—Betamethasone—psoriasis	0.0005	0.00158	CcSEcCtD
Fingolimod—Cardiac arrest—Dexamethasone—psoriasis	0.0005	0.00158	CcSEcCtD
Fingolimod—Infection—Hydroxyurea—psoriasis	0.000499	0.00157	CcSEcCtD
Fingolimod—Back pain—Mycophenolic acid—psoriasis	0.000499	0.00157	CcSEcCtD
Fingolimod—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000498	0.0021	CbGpPWpGaD
Fingolimod—Nervous system disorder—Hydroxyurea—psoriasis	0.000493	0.00155	CcSEcCtD
Fingolimod—Diarrhoea—Calcitriol—psoriasis	0.000492	0.00155	CcSEcCtD
Fingolimod—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000491	0.00207	CbGpPWpGaD
Fingolimod—SPHK1—PDGFR-beta signaling pathway—STAT3—psoriasis	0.000489	0.00206	CbGpPWpGaD
Fingolimod—Sinusitis—Mycophenolate mofetil—psoriasis	0.000488	0.00154	CcSEcCtD
Fingolimod—Skin disorder—Hydroxyurea—psoriasis	0.000488	0.00154	CcSEcCtD
Fingolimod—Vision blurred—Mycophenolic acid—psoriasis	0.000486	0.00153	CcSEcCtD
Fingolimod—Bronchitis—Triamcinolone—psoriasis	0.000482	0.00152	CcSEcCtD
Fingolimod—Weight decreased—Hydrocortisone—psoriasis	0.000481	0.00152	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—HCAR2—psoriasis	0.00048	0.00202	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CCL20—psoriasis	0.000477	0.00201	CbGpPWpGaD
Fingolimod—Bradycardia—Mycophenolate mofetil—psoriasis	0.000476	0.0015	CcSEcCtD
Fingolimod—Infestation—Hydrocortisone—psoriasis	0.000474	0.00149	CcSEcCtD
Fingolimod—Infestation NOS—Hydrocortisone—psoriasis	0.000474	0.00149	CcSEcCtD
Fingolimod—S1PR4—G alpha (i) signalling events—CXCL8—psoriasis	0.000474	0.002	CbGpPWpGaD
Fingolimod—Connective tissue disorder—Cyclosporine—psoriasis	0.000471	0.00148	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—TAGAP—psoriasis	0.00047	0.00198	CbGpPWpGaD
Fingolimod—Leukopenia—Mycophenolic acid—psoriasis	0.000461	0.00145	CcSEcCtD
Fingolimod—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000459	0.00145	CcSEcCtD
Fingolimod—Asthenia—Acitretin—psoriasis	0.000459	0.00145	CcSEcCtD
Fingolimod—S1PR5—G alpha (i) signalling events—CXCL8—psoriasis	0.000456	0.00192	CbGpPWpGaD
Fingolimod—S1PR3—G alpha (i) signalling events—CXCL8—psoriasis	0.000456	0.00192	CbGpPWpGaD
Fingolimod—Palpitations—Mycophenolic acid—psoriasis	0.000456	0.00144	CcSEcCtD
Fingolimod—SPHK1—Dexamethasone—Hydrocortisone—psoriasis	0.000453	0.0381	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Hydrocortisone—psoriasis	0.000453	0.0381	CbGdCrCtD
Fingolimod—Pruritus—Acitretin—psoriasis	0.000453	0.00143	CcSEcCtD
Fingolimod—Pruritus—Fluocinolone Acetonide—psoriasis	0.000451	0.00142	CcSEcCtD
Fingolimod—Headache—Calcitriol—psoriasis	0.000451	0.00142	CcSEcCtD
Fingolimod—Cough—Mycophenolic acid—psoriasis	0.00045	0.00142	CcSEcCtD
Fingolimod—Dyspnoea—Hydroxyurea—psoriasis	0.000448	0.00141	CcSEcCtD
Fingolimod—Hypertension—Mycophenolic acid—psoriasis	0.000445	0.0014	CcSEcCtD
Fingolimod—Bradycardia—Prednisolone—psoriasis	0.000444	0.0014	CcSEcCtD
Fingolimod—Diarrhoea—Acitretin—psoriasis	0.000438	0.00138	CcSEcCtD
Fingolimod—Eye disorder—Mycophenolate mofetil—psoriasis	0.000437	0.00138	CcSEcCtD
Fingolimod—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000437	0.00138	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000436	0.00137	CcSEcCtD
Fingolimod—Cardiac arrest—Prednisone—psoriasis	0.000435	0.00137	CcSEcCtD
Fingolimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000435	0.00183	CbGpPWpGaD
Fingolimod—Angiopathy—Cyclosporine—psoriasis	0.000435	0.00137	CcSEcCtD
Fingolimod—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000434	0.00137	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000434	0.00137	CcSEcCtD
Fingolimod—Bradycardia—Hydrocortisone—psoriasis	0.000433	0.00137	CcSEcCtD
Fingolimod—Fatigue—Hydroxyurea—psoriasis	0.000433	0.00136	CcSEcCtD
Fingolimod—Mediastinal disorder—Cyclosporine—psoriasis	0.000432	0.00136	CcSEcCtD
Fingolimod—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.00043	0.00181	CbGpPWpGaD
Fingolimod—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000429	0.00181	CbGpPWpGaD
Fingolimod—Angiopathy—Mycophenolate mofetil—psoriasis	0.000424	0.00134	CcSEcCtD
Fingolimod—Alopecia—Cyclosporine—psoriasis	0.000423	0.00133	CcSEcCtD
Fingolimod—Dizziness—Acitretin—psoriasis	0.000423	0.00133	CcSEcCtD
Fingolimod—Dizziness—Fluocinolone Acetonide—psoriasis	0.000422	0.00133	CcSEcCtD
Fingolimod—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000421	0.00133	CcSEcCtD
Fingolimod—SPHK1—Dexamethasone—Betamethasone—psoriasis	0.000421	0.0353	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Dexamethasone—psoriasis	0.000421	0.0353	CbGdCrCtD
Fingolimod—Mental disorder—Cyclosporine—psoriasis	0.00042	0.00132	CcSEcCtD
Fingolimod—Connective tissue disorder—Hydrocortisone—psoriasis	0.000418	0.00132	CcSEcCtD
Fingolimod—Infection—Mycophenolic acid—psoriasis	0.000418	0.00132	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—TAGAP—psoriasis	0.000416	0.00175	CbGpPWpGaD
Fingolimod—S1PR1—G alpha (i) signalling events—CXCL8—psoriasis	0.000414	0.00174	CbGpPWpGaD
Fingolimod—Alopecia—Mycophenolate mofetil—psoriasis	0.000413	0.0013	CcSEcCtD
Fingolimod—Nervous system disorder—Mycophenolic acid—psoriasis	0.000413	0.0013	CcSEcCtD
Fingolimod—SPHK1—Betamethasone—Triamcinolone—psoriasis	0.000411	0.0345	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Triamcinolone—psoriasis	0.000411	0.0345	CbGdCrCtD
Fingolimod—Weight decreased—Dexamethasone—psoriasis	0.000411	0.0013	CcSEcCtD
Fingolimod—Weight decreased—Betamethasone—psoriasis	0.000411	0.0013	CcSEcCtD
Fingolimod—Mental disorder—Mycophenolate mofetil—psoriasis	0.000409	0.00129	CcSEcCtD
Fingolimod—Skin disorder—Mycophenolic acid—psoriasis	0.000409	0.00129	CcSEcCtD
Fingolimod—Bradycardia—Triamcinolone—psoriasis	0.000408	0.00129	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Prednisone—psoriasis	0.000404	0.00127	CcSEcCtD
Fingolimod—Headache—Acitretin—psoriasis	0.000401	0.00126	CcSEcCtD
Fingolimod—Headache—Fluocinolone Acetonide—psoriasis	0.0004	0.00126	CcSEcCtD
Fingolimod—Eye disorder—Hydrocortisone—psoriasis	0.000398	0.00125	CcSEcCtD
Fingolimod—Back pain—Mycophenolate mofetil—psoriasis	0.000394	0.00124	CcSEcCtD
Fingolimod—Hypotension—Mycophenolic acid—psoriasis	0.000393	0.00124	CcSEcCtD
Fingolimod—Vision blurred—Cyclosporine—psoriasis	0.000393	0.00124	CcSEcCtD
Fingolimod—Cerebrovascular accident—Methotrexate—psoriasis	0.000391	0.00123	CcSEcCtD
Fingolimod—SPHK1—Dexamethasone—Prednisone—psoriasis	0.00039	0.0328	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Prednisone—psoriasis	0.00039	0.0328	CbGdCrCtD
Fingolimod—SPHK1—VEGFA-VEGFR2 Pathway—IL6—psoriasis	0.000387	0.00163	CbGpPWpGaD
Fingolimod—SPHK1—Betamethasone—Prednisolone—psoriasis	0.000381	0.032	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Prednisolone—psoriasis	0.000381	0.032	CbGdCrCtD
Fingolimod—SPHK1—Metabolism of proteins—ACE—psoriasis	0.000378	0.00159	CbGpPWpGaD
Fingolimod—Paraesthesia—Mycophenolic acid—psoriasis	0.000378	0.00119	CcSEcCtD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000377	0.00159	CbGpPWpGaD
Fingolimod—Dyspnoea—Mycophenolic acid—psoriasis	0.000375	0.00118	CcSEcCtD
Fingolimod—Leukopenia—Cyclosporine—psoriasis	0.000373	0.00118	CcSEcCtD
Fingolimod—Mental disorder—Hydrocortisone—psoriasis	0.000373	0.00118	CcSEcCtD
Fingolimod—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00037	0.00156	CbGpPWpGaD
Fingolimod—Bradycardia—Dexamethasone—psoriasis	0.00037	0.00117	CcSEcCtD
Fingolimod—Bradycardia—Betamethasone—psoriasis	0.00037	0.00117	CcSEcCtD
Fingolimod—SPHK1—Signaling by VEGF—IL6—psoriasis	0.000365	0.00154	CbGpPWpGaD
Fingolimod—Leukopenia—Mycophenolate mofetil—psoriasis	0.000364	0.00115	CcSEcCtD
Fingolimod—Cough—Cyclosporine—psoriasis	0.000364	0.00115	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000363	0.00114	CcSEcCtD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000363	0.00153	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000363	0.00153	CbGpPWpGaD
Fingolimod—Fatigue—Mycophenolic acid—psoriasis	0.000363	0.00114	CcSEcCtD
Fingolimod—Asthenia—Hydroxyurea—psoriasis	0.00036	0.00114	CcSEcCtD
Fingolimod—Hypertension—Cyclosporine—psoriasis	0.00036	0.00113	CcSEcCtD
Fingolimod—Palpitations—Mycophenolate mofetil—psoriasis	0.00036	0.00113	CcSEcCtD
Fingolimod—Weight decreased—Prednisone—psoriasis	0.000358	0.00113	CcSEcCtD
Fingolimod—Vision blurred—Prednisolone—psoriasis	0.000358	0.00113	CcSEcCtD
Fingolimod—Cough—Mycophenolate mofetil—psoriasis	0.000355	0.00112	CcSEcCtD
Fingolimod—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000354	0.00149	CbGpPWpGaD
Fingolimod—Liver function test abnormal—Methotrexate—psoriasis	0.000353	0.00111	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000353	0.00111	CcSEcCtD
Fingolimod—Depression—Prednisone—psoriasis	0.000352	0.00111	CcSEcCtD
Fingolimod—Hypertension—Mycophenolate mofetil—psoriasis	0.000351	0.00111	CcSEcCtD
Fingolimod—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000349	0.00147	CbGpPWpGaD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000344	0.00108	CcSEcCtD
Fingolimod—Diarrhoea—Hydroxyurea—psoriasis	0.000344	0.00108	CcSEcCtD
Fingolimod—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000343	0.00144	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—CARM1—psoriasis	0.000342	0.00144	CbGpPWpGaD
Fingolimod—Eye disorder—Betamethasone—psoriasis	0.00034	0.00107	CcSEcCtD
Fingolimod—Eye disorder—Dexamethasone—psoriasis	0.00034	0.00107	CcSEcCtD
Fingolimod—Infection—Cyclosporine—psoriasis	0.000338	0.00107	CcSEcCtD
Fingolimod—Back pain—Triamcinolone—psoriasis	0.000338	0.00106	CcSEcCtD
Fingolimod—Nervous system disorder—Cyclosporine—psoriasis	0.000334	0.00105	CcSEcCtD
Fingolimod—Dizziness—Hydroxyurea—psoriasis	0.000332	0.00105	CcSEcCtD
Fingolimod—Skin disorder—Cyclosporine—psoriasis	0.000331	0.00104	CcSEcCtD
Fingolimod—Angiopathy—Dexamethasone—psoriasis	0.00033	0.00104	CcSEcCtD
Fingolimod—Angiopathy—Betamethasone—psoriasis	0.00033	0.00104	CcSEcCtD
Fingolimod—Infection—Mycophenolate mofetil—psoriasis	0.00033	0.00104	CcSEcCtD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000329	0.00139	CbGpPWpGaD
Fingolimod—Hypertension—Prednisolone—psoriasis	0.000328	0.00103	CcSEcCtD
Fingolimod—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000326	0.00103	CcSEcCtD
Fingolimod—Skin disorder—Mycophenolate mofetil—psoriasis	0.000323	0.00102	CcSEcCtD
Fingolimod—Bradycardia—Prednisone—psoriasis	0.000323	0.00102	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—CCL20—psoriasis	0.000322	0.00136	CbGpPWpGaD
Fingolimod—Alopecia—Betamethasone—psoriasis	0.000321	0.00101	CcSEcCtD
Fingolimod—Alopecia—Dexamethasone—psoriasis	0.000321	0.00101	CcSEcCtD
Fingolimod—Hypertension—Hydrocortisone—psoriasis	0.00032	0.00101	CcSEcCtD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000317	0.00133	CbGpPWpGaD
Fingolimod—Headache—Hydroxyurea—psoriasis	0.000315	0.000992	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000313	0.000987	CcSEcCtD
Fingolimod—Connective tissue disorder—Prednisone—psoriasis	0.000311	0.000981	CcSEcCtD
Fingolimod—Hypotension—Mycophenolate mofetil—psoriasis	0.00031	0.000978	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—CCL20—psoriasis	0.00031	0.00131	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCL20—psoriasis	0.00031	0.00131	CbGpPWpGaD
Fingolimod—Paraesthesia—Cyclosporine—psoriasis	0.000306	0.000963	CcSEcCtD
Fingolimod—Cough—Triamcinolone—psoriasis	0.000305	0.00096	CcSEcCtD
Fingolimod—Dyspnoea—Cyclosporine—psoriasis	0.000303	0.000956	CcSEcCtD
Fingolimod—Asthenia—Mycophenolic acid—psoriasis	0.000302	0.000951	CcSEcCtD
Fingolimod—Hypertension—Triamcinolone—psoriasis	0.000301	0.000949	CcSEcCtD
Fingolimod—Infection—Hydrocortisone—psoriasis	0.000301	0.000947	CcSEcCtD
Fingolimod—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000298	0.000939	CcSEcCtD
Fingolimod—Pruritus—Mycophenolic acid—psoriasis	0.000298	0.000938	CcSEcCtD
Fingolimod—Nervous system disorder—Hydrocortisone—psoriasis	0.000297	0.000935	CcSEcCtD
Fingolimod—Pneumonia—Methotrexate—psoriasis	0.000297	0.000935	CcSEcCtD
Fingolimod—Eye disorder—Prednisone—psoriasis	0.000296	0.000933	CcSEcCtD
Fingolimod—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000296	0.000933	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—CARM1—psoriasis	0.000295	0.00124	CbGpPWpGaD
Fingolimod—Infestation NOS—Methotrexate—psoriasis	0.000295	0.000929	CcSEcCtD
Fingolimod—Infestation—Methotrexate—psoriasis	0.000295	0.000929	CcSEcCtD
Fingolimod—Depression—Methotrexate—psoriasis	0.000294	0.000927	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000294	0.000926	CcSEcCtD
Fingolimod—Skin disorder—Hydrocortisone—psoriasis	0.000294	0.000926	CcSEcCtD
Fingolimod—Fatigue—Cyclosporine—psoriasis	0.000293	0.000925	CcSEcCtD
Fingolimod—Diarrhoea—Mycophenolic acid—psoriasis	0.000288	0.000907	CcSEcCtD
Fingolimod—Angiopathy—Prednisone—psoriasis	0.000287	0.000906	CcSEcCtD
Fingolimod—S1PR4—GPCR ligand binding—CXCL8—psoriasis	0.000287	0.00121	CbGpPWpGaD
Fingolimod—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000287	0.000903	CcSEcCtD
Fingolimod—Infection—Triamcinolone—psoriasis	0.000283	0.000892	CcSEcCtD
Fingolimod—Hypotension—Hydrocortisone—psoriasis	0.000283	0.000891	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—CCL20—psoriasis	0.000282	0.00119	CbGpPWpGaD
Fingolimod—Alopecia—Prednisone—psoriasis	0.00028	0.000882	CcSEcCtD
Fingolimod—Dizziness—Mycophenolic acid—psoriasis	0.000278	0.000877	CcSEcCtD
Fingolimod—Paraesthesia—Prednisolone—psoriasis	0.000278	0.000876	CcSEcCtD
Fingolimod—Mental disorder—Prednisone—psoriasis	0.000278	0.000874	CcSEcCtD
Fingolimod—S1PR3—GPCR ligand binding—CXCL8—psoriasis	0.000276	0.00116	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—CXCL8—psoriasis	0.000276	0.00116	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000276	0.00116	CbGpPWpGaD
Fingolimod—Hypertension—Dexamethasone—psoriasis	0.000273	0.000861	CcSEcCtD
Fingolimod—Hypertension—Betamethasone—psoriasis	0.000273	0.000861	CcSEcCtD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000272	0.00114	CbGpPWpGaD
Fingolimod—Paraesthesia—Hydrocortisone—psoriasis	0.000272	0.000856	CcSEcCtD
Fingolimod—Headache—Mycophenolic acid—psoriasis	0.000264	0.00083	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000261	0.000823	CcSEcCtD
Fingolimod—Fatigue—Hydrocortisone—psoriasis	0.000261	0.000822	CcSEcCtD
Fingolimod—Vision blurred—Prednisone—psoriasis	0.00026	0.000819	CcSEcCtD
Fingolimod—Infection—Dexamethasone—psoriasis	0.000257	0.000809	CcSEcCtD
Fingolimod—Infection—Betamethasone—psoriasis	0.000257	0.000809	CcSEcCtD
Fingolimod—Paraesthesia—Triamcinolone—psoriasis	0.000256	0.000806	CcSEcCtD
Fingolimod—Dyspnoea—Triamcinolone—psoriasis	0.000254	0.0008	CcSEcCtD
Fingolimod—Nervous system disorder—Betamethasone—psoriasis	0.000253	0.000799	CcSEcCtD
Fingolimod—Nervous system disorder—Dexamethasone—psoriasis	0.000253	0.000799	CcSEcCtD
Fingolimod—SPHK1—Metabolism—CARM1—psoriasis	0.000253	0.00107	CbGpPWpGaD
Fingolimod—S1PR1—GPCR ligand binding—CXCL8—psoriasis	0.000251	0.00106	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCL20—psoriasis	0.000249	0.00105	CbGpPWpGaD
Fingolimod—Eye disorder—Methotrexate—psoriasis	0.000247	0.00078	CcSEcCtD
Fingolimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000247	0.00104	CbGpPWpGaD
Fingolimod—Cardiac disorder—Methotrexate—psoriasis	0.000246	0.000774	CcSEcCtD
Fingolimod—Fatigue—Triamcinolone—psoriasis	0.000246	0.000774	CcSEcCtD
Fingolimod—Asthenia—Cyclosporine—psoriasis	0.000244	0.000769	CcSEcCtD
Fingolimod—Hypotension—Betamethasone—psoriasis	0.000242	0.000761	CcSEcCtD
Fingolimod—Hypotension—Dexamethasone—psoriasis	0.000242	0.000761	CcSEcCtD
Fingolimod—Pruritus—Cyclosporine—psoriasis	0.000241	0.000759	CcSEcCtD
Fingolimod—Angiopathy—Methotrexate—psoriasis	0.00024	0.000757	CcSEcCtD
Fingolimod—Mediastinal disorder—Methotrexate—psoriasis	0.000239	0.000752	CcSEcCtD
Fingolimod—Asthenia—Mycophenolate mofetil—psoriasis	0.000238	0.000751	CcSEcCtD
Fingolimod—Hypertension—Prednisone—psoriasis	0.000238	0.00075	CcSEcCtD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000237	0.000997	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—LEP—psoriasis	0.000235	0.000989	CbGpPWpGaD
Fingolimod—Pruritus—Mycophenolate mofetil—psoriasis	0.000235	0.00074	CcSEcCtD
Fingolimod—Alopecia—Methotrexate—psoriasis	0.000234	0.000737	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000233	0.000735	CcSEcCtD
Fingolimod—Diarrhoea—Cyclosporine—psoriasis	0.000233	0.000734	CcSEcCtD
Fingolimod—Paraesthesia—Betamethasone—psoriasis	0.000232	0.000731	CcSEcCtD
Fingolimod—Paraesthesia—Dexamethasone—psoriasis	0.000232	0.000731	CcSEcCtD
Fingolimod—Mental disorder—Methotrexate—psoriasis	0.000232	0.000731	CcSEcCtD
Fingolimod—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000231	0.000973	CbGpPWpGaD
Fingolimod—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000228	0.00096	CbGpPWpGaD
Fingolimod—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000227	0.000716	CcSEcCtD
Fingolimod—Dizziness—Cyclosporine—psoriasis	0.000225	0.000709	CcSEcCtD
Fingolimod—Infection—Prednisone—psoriasis	0.000224	0.000704	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000223	0.000703	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Betamethasone—psoriasis	0.000223	0.000703	CcSEcCtD
Fingolimod—Back pain—Methotrexate—psoriasis	0.000223	0.000702	CcSEcCtD
Fingolimod—Fatigue—Dexamethasone—psoriasis	0.000223	0.000702	CcSEcCtD
Fingolimod—Fatigue—Betamethasone—psoriasis	0.000223	0.000702	CcSEcCtD
Fingolimod—Nervous system disorder—Prednisone—psoriasis	0.000221	0.000695	CcSEcCtD
Fingolimod—Dizziness—Mycophenolate mofetil—psoriasis	0.00022	0.000692	CcSEcCtD
Fingolimod—Skin disorder—Prednisone—psoriasis	0.000219	0.000689	CcSEcCtD
Fingolimod—Vision blurred—Methotrexate—psoriasis	0.000217	0.000684	CcSEcCtD
Fingolimod—Asthenia—Hydrocortisone—psoriasis	0.000217	0.000684	CcSEcCtD
Fingolimod—Pruritus—Hydrocortisone—psoriasis	0.000214	0.000674	CcSEcCtD
Fingolimod—Headache—Cyclosporine—psoriasis	0.000213	0.000672	CcSEcCtD
Fingolimod—CYP4F12—Metabolism—CAT—psoriasis	0.00021	0.000885	CbGpPWpGaD
Fingolimod—Headache—Mycophenolate mofetil—psoriasis	0.000208	0.000655	CcSEcCtD
Fingolimod—Diarrhoea—Hydrocortisone—psoriasis	0.000207	0.000652	CcSEcCtD
Fingolimod—Leukopenia—Methotrexate—psoriasis	0.000206	0.00065	CcSEcCtD
Fingolimod—Dizziness—Prednisolone—psoriasis	0.000205	0.000645	CcSEcCtD
Fingolimod—Asthenia—Triamcinolone—psoriasis	0.000204	0.000644	CcSEcCtD
Fingolimod—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000204	0.000858	CbGpPWpGaD
Fingolimod—Paraesthesia—Prednisone—psoriasis	0.000202	0.000637	CcSEcCtD
Fingolimod—Pruritus—Triamcinolone—psoriasis	0.000202	0.000635	CcSEcCtD
Fingolimod—Cough—Methotrexate—psoriasis	0.000201	0.000634	CcSEcCtD
Fingolimod—Dizziness—Hydrocortisone—psoriasis	0.0002	0.00063	CcSEcCtD
Fingolimod—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000199	0.000839	CbGpPWpGaD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000195	0.000614	CcSEcCtD
Fingolimod—Fatigue—Prednisone—psoriasis	0.000194	0.000611	CcSEcCtD
Fingolimod—Headache—Prednisolone—psoriasis	0.000194	0.000611	CcSEcCtD
Fingolimod—Headache—Hydrocortisone—psoriasis	0.00019	0.000597	CcSEcCtD
Fingolimod—Dizziness—Triamcinolone—psoriasis	0.000188	0.000593	CcSEcCtD
Fingolimod—Infection—Methotrexate—psoriasis	0.000187	0.000589	CcSEcCtD
Fingolimod—Asthenia—Betamethasone—psoriasis	0.000185	0.000584	CcSEcCtD
Fingolimod—Asthenia—Dexamethasone—psoriasis	0.000185	0.000584	CcSEcCtD
Fingolimod—Nervous system disorder—Methotrexate—psoriasis	0.000184	0.000581	CcSEcCtD
Fingolimod—Pruritus—Dexamethasone—psoriasis	0.000183	0.000576	CcSEcCtD
Fingolimod—Pruritus—Betamethasone—psoriasis	0.000183	0.000576	CcSEcCtD
Fingolimod—Skin disorder—Methotrexate—psoriasis	0.000183	0.000576	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—CAT—psoriasis	0.000181	0.000764	CbGpPWpGaD
Fingolimod—Headache—Triamcinolone—psoriasis	0.000178	0.000562	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—SOCS1—psoriasis	0.000177	0.000747	CbGpPWpGaD
Fingolimod—Diarrhoea—Dexamethasone—psoriasis	0.000177	0.000557	CcSEcCtD
Fingolimod—Diarrhoea—Betamethasone—psoriasis	0.000177	0.000557	CcSEcCtD
Fingolimod—Hypotension—Methotrexate—psoriasis	0.000176	0.000554	CcSEcCtD
Fingolimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000172	0.000724	CbGpPWpGaD
Fingolimod—Dizziness—Betamethasone—psoriasis	0.000171	0.000538	CcSEcCtD
Fingolimod—Dizziness—Dexamethasone—psoriasis	0.000171	0.000538	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—SOCS1—psoriasis	0.000171	0.000719	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—SOCS1—psoriasis	0.000171	0.000719	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—TYK2—psoriasis	0.000169	0.000712	CbGpPWpGaD
Fingolimod—Paraesthesia—Methotrexate—psoriasis	0.000169	0.000532	CcSEcCtD
Fingolimod—Dyspnoea—Methotrexate—psoriasis	0.000168	0.000528	CcSEcCtD
Fingolimod—CYP4F12—Metabolism—APOE—psoriasis	0.000163	0.000687	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—TYK2—psoriasis	0.000163	0.000685	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—TYK2—psoriasis	0.000163	0.000685	CbGpPWpGaD
Fingolimod—Gastrointestinal disorder—Methotrexate—psoriasis	0.000162	0.000512	CcSEcCtD
Fingolimod—S1PR4—GPCR downstream signaling—CXCL8—psoriasis	0.000162	0.000683	CbGpPWpGaD
Fingolimod—Fatigue—Methotrexate—psoriasis	0.000162	0.000511	CcSEcCtD
Fingolimod—Headache—Betamethasone—psoriasis	0.000162	0.00051	CcSEcCtD
Fingolimod—Headache—Dexamethasone—psoriasis	0.000162	0.00051	CcSEcCtD
Fingolimod—Asthenia—Prednisone—psoriasis	0.000161	0.000509	CcSEcCtD
Fingolimod—Pruritus—Prednisone—psoriasis	0.000159	0.000502	CcSEcCtD
Fingolimod—SPHK1—Metabolism of proteins—CXCL8—psoriasis	0.000156	0.000657	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—CXCL8—psoriasis	0.000156	0.000657	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—CXCL8—psoriasis	0.000156	0.000657	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—CAT—psoriasis	0.000156	0.000656	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—SOCS1—psoriasis	0.000155	0.000653	CbGpPWpGaD
Fingolimod—Diarrhoea—Prednisone—psoriasis	0.000154	0.000485	CcSEcCtD
Fingolimod—Dizziness—Prednisone—psoriasis	0.000149	0.000469	CcSEcCtD
Fingolimod—S1PR1—Signaling by GPCR—TYK2—psoriasis	0.000148	0.000622	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—CXCL8—psoriasis	0.000147	0.00062	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—PPARG—psoriasis	0.000142	0.000599	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CXCL8—psoriasis	0.000142	0.000597	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CXCL8—psoriasis	0.000142	0.000597	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—CXCL8—psoriasis	0.000142	0.000597	CbGpPWpGaD
Fingolimod—Headache—Prednisone—psoriasis	0.000141	0.000444	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—APOE—psoriasis	0.000141	0.000593	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—SOCS1—psoriasis	0.000137	0.000578	CbGpPWpGaD
Fingolimod—Asthenia—Methotrexate—psoriasis	0.000135	0.000425	CcSEcCtD
Fingolimod—Pruritus—Methotrexate—psoriasis	0.000133	0.000419	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—APOE—psoriasis	0.000131	0.000551	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—LEP—psoriasis	0.000131	0.000551	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CXCL8—psoriasis	0.000129	0.000542	CbGpPWpGaD
Fingolimod—Diarrhoea—Methotrexate—psoriasis	0.000129	0.000405	CcSEcCtD
Fingolimod—S1PR3—Signaling Pathways—APOE—psoriasis	0.000126	0.000531	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—LEP—psoriasis	0.000126	0.000531	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—APOE—psoriasis	0.000126	0.000531	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—LEP—psoriasis	0.000126	0.000531	CbGpPWpGaD
Fingolimod—Dizziness—Methotrexate—psoriasis	0.000124	0.000392	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—PPARG—psoriasis	0.000123	0.000517	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—NFKBIA—psoriasis	0.000122	0.000514	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—APOE—psoriasis	0.000121	0.00051	CbGpPWpGaD
Fingolimod—Headache—Methotrexate—psoriasis	0.000118	0.000371	CcSEcCtD
Fingolimod—S1PR3—Signaling Pathways—NFKBIA—psoriasis	0.000117	0.000494	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—NFKBIA—psoriasis	0.000117	0.000494	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—LEP—psoriasis	0.000114	0.000482	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—APOE—psoriasis	0.000114	0.000482	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—NFKBIA—psoriasis	0.000107	0.000449	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—PPARG—psoriasis	0.000106	0.000444	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—APOE—psoriasis	0.000101	0.000426	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—LEP—psoriasis	0.000101	0.000426	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—NDUFA5—psoriasis	0.0001	0.000422	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—TYK2—psoriasis	9.99e-05	0.000421	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TYK2—psoriasis	9.62e-05	0.000405	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—TYK2—psoriasis	9.62e-05	0.000405	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—NFKBIA—psoriasis	9.44e-05	0.000397	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—TYK2—psoriasis	8.73e-05	0.000368	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CXCL8—psoriasis	8.7e-05	0.000366	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CYP2S1—psoriasis	8.52e-05	0.000359	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CXCL8—psoriasis	8.38e-05	0.000353	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CXCL8—psoriasis	8.38e-05	0.000353	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—IL6—psoriasis	8.27e-05	0.000348	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—JUN—psoriasis	8.09e-05	0.00034	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—IL6—psoriasis	7.96e-05	0.000335	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—IL6—psoriasis	7.96e-05	0.000335	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—NFKB1—psoriasis	7.79e-05	0.000328	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—JUN—psoriasis	7.79e-05	0.000328	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—JUN—psoriasis	7.79e-05	0.000328	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—TYK2—psoriasis	7.73e-05	0.000325	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CXCL8—psoriasis	7.61e-05	0.00032	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—NFKB1—psoriasis	7.49e-05	0.000315	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—NFKB1—psoriasis	7.49e-05	0.000315	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—IL6—psoriasis	7.23e-05	0.000304	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—NDUFA5—psoriasis	7.11e-05	0.000299	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—JUN—psoriasis	7.07e-05	0.000298	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—VEGFA—psoriasis	7.07e-05	0.000297	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—STAT3—psoriasis	7e-05	0.000295	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—NFKB1—psoriasis	6.81e-05	0.000286	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—VEGFA—psoriasis	6.8e-05	0.000286	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—VEGFA—psoriasis	6.8e-05	0.000286	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—STAT3—psoriasis	6.74e-05	0.000284	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—STAT3—psoriasis	6.74e-05	0.000284	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CXCL8—psoriasis	6.73e-05	0.000283	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—JUN—psoriasis	6.26e-05	0.000263	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—VEGFA—psoriasis	6.18e-05	0.00026	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—STAT3—psoriasis	6.12e-05	0.000257	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CYP2S1—psoriasis	6.05e-05	0.000254	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—NFKB1—psoriasis	6.02e-05	0.000254	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—VEGFA—psoriasis	5.47e-05	0.00023	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—STAT3—psoriasis	5.41e-05	0.000228	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—TP53—psoriasis	5.34e-05	0.000225	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TP53—psoriasis	5.14e-05	0.000216	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—TP53—psoriasis	5.14e-05	0.000216	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—IL6—psoriasis	4.89e-05	0.000206	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—IL6—psoriasis	4.7e-05	0.000198	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—IL6—psoriasis	4.7e-05	0.000198	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—TP53—psoriasis	4.67e-05	0.000196	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—NDUFA5—psoriasis	4.65e-05	0.000196	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—IL6—psoriasis	4.27e-05	0.00018	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CARM1—psoriasis	4.16e-05	0.000175	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—TP53—psoriasis	4.13e-05	0.000174	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CYP2S1—psoriasis	3.95e-05	0.000166	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—IL6—psoriasis	3.78e-05	0.000159	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CARM1—psoriasis	2.95e-05	0.000124	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CAT—psoriasis	2.56e-05	0.000108	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—APOE—psoriasis	1.99e-05	8.37e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CARM1—psoriasis	1.93e-05	8.13e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CAT—psoriasis	1.82e-05	7.64e-05	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—PPARG—psoriasis	1.73e-05	7.29e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—APOE—psoriasis	1.41e-05	5.94e-05	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—PPARG—psoriasis	1.23e-05	5.17e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CAT—psoriasis	1.19e-05	5e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—APOE—psoriasis	9.23e-06	3.88e-05	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—PPARG—psoriasis	8.04e-06	3.38e-05	CbGpPWpGaD
